首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical pharmacology in drug development

缩写:CLIN PHARM DRUG DEV

ISSN:2160-7648

e-ISSN:2160-7648

IF/分区:1.7/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引1332
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Mendel Jansen,Jeanne Mendell,Alexander Currie et al. Mendel Jansen et al.
Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central...
Hiroko Tabuchi,Sari Shiba,Sanae Yasuda et al. Hiroko Tabuchi et al.
Perampanel is a highly selective, orally active, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that has been approved in many countries as a treatment for partial-onset seizures and primary general...
Jeremy Dennison,Adeep Puri,Steven Warrington et al. Jeremy Dennison et al.
Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8. We conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6. The montelukast study examined ...
Hiroko Ino,Akira Endo,Akira Wakamatsu et al. Hiroko Ino et al.
GSK2330672 is an inhibitor of the ileal bile acid transporter, designed to have minimal systemic exposure, and is under development as a potential therapeutic for pruritus associated with primary biliary cholangitis and other cholestatic li...
Guangli Ma,Rujia Xie,Bruce Strober et al. Guangli Ma et al.
Tofacitinib is an oral Janus kinase (JAK) inhibitor. This study characterized the pharmacokinetics of tofacitinib in patients with psoriasis and evaluated the impact of patient factors on disposition. Pooled phase 2/3 data (2981 patients: 9...
Geoffrey I Shapiro,Rebecca S Kristeleit,Howard A Burris et al. Geoffrey I Shapiro et al.
The phase 1-2 study CO-338-010 (Study 10; NCT01482715) is evaluating single-agent rucaparib, a poly(ADP-ribose) polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part 1), we ch...
Ofer Spiegelstein,Dorit Mimrod,Laura Rabinovich et al. Ofer Spiegelstein et al.
In this randomized double-blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in development for multiple sclerosis and Huntington disease, on the QTc interval. Subject...
Vikas Kumar Dawra,David L Cutler,Susan Zhou et al. Vikas Kumar Dawra et al.
Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected to be coadministered with sitagliptin, metformin, glimepiride, and/or simvastatin. Four separate open-label, ra...
Joseph Massarella,Jay Ariyawansa,Jaya Natarajan et al. Joseph Massarella et al.
We evaluated the effects of therapeutic and supratherapeutic doses of tramadol hydrochloride on the corrected QT (QTc) interval in healthy adults (aged 18-55 years) in a randomized, phase I, double-blind, placebo- and positive-controlled, m...
A E Muller,N Punt,M Engelhardt et al. A E Muller et al.
Ceftobiprole is a broad-spectrum cephalosporin. The objective of this study was to test the hypothesis that the pharmacokinetics (PK) and exposure of ceftobiprole in Asian subjects are similar to those in non-Asian subjects. Three approache...